Recombinant Anti-vascular Amyloid 1-42 antibody [mOC31] - Conformation-Specific (ab201059)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [mOC31] to vascular Amyloid 1-42 - Conformation-Specific
- Suitable for: Dot blot, IHC-P, IHC-FrFl
- Reacts with: Mouse, Human
Overview
-
Product name
Anti-vascular Amyloid 1-42 antibody [mOC31] - Conformation-Specific
See all vascular Amyloid 1-42 primary antibodies -
Description
Rabbit monoclonal [mOC31] to vascular Amyloid 1-42 - Conformation-Specific -
Host species
Rabbit -
Tested applications
Suitable for: Dot blot, IHC-P, IHC-FrFlmore details -
Species reactivity
Reacts with: Mouse, Human -
Immunogen
Other Immunogen Type corresponding to Human vascular Amyloid 1-42. Amyloid beta 1-42 fibrils were used as the immunogen.
Database link: P05067 -
Positive control
- beta Amyloid (Aß) 1-42 IHC-P: FFPE human brain Alzheimer
-
General notes
This antibody was developed as part of a collaboration between Abcam and Professor Charles Glabe, UC Irvine.
ab201059 recognizes a conformation-specific discontinuous epitope of beta Amyloid that maps to segments EFGRHSGY and ED (Hatami et al. 2014). It specifically recognizes a subset of vascular amyloid that does not colocalize with thioflavin S (Hatami et al. 2014, McLean et al. 2013).
For further information on the immunogen, please refer to Hatami et al. 2014 and Kayed et al. 2007.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol, 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
mOC31 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
Applications
Our Abpromise guarantee covers the use of ab201059 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Dot blot | 1/100. | |
IHC-P | 1/250 - 1/500. Do not perform antigen retrieval. | |
IHC-FrFl | Use at an assay dependent concentration. |
Target
-
Alternative names
- A4 antibody
- A4_HUMAN antibody
- AAA antibody
see all
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-vascular Amyloid 1-42 antibody [mOC31] - Conformation-Specific (ab201059)
IHC image of beta Amyloid staining in a formalin fixed paraffin embedded human Alzheimer brain tissue section, performed on a Leica Bond™ system using the standard protocol F. No antigen retrieval was performed prior to staining. The section was incubated with ab201090 at 1/500 dilution for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
Image showing staining of vascular Amyloid as described in Hatami et al. 2014
-
Dot blot analysis of beta Amyloid 1-42 labeled with ab201059 at 1/100 dilution.
Lane 1: beta Amyloid (Aβ) 1-40.
Lane 2: beta Amyloid (Aβ) 1-42.
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/5000 dilution was used as secondary antibody.
Blocking and diluting buffer: 5% NFDM/TBST.
Exposure time: 1 minute.Antibody reactivity was assessed using a dot blot, which is a non-quantitative method that maintains the native conformation of beta Amyloid. Beta Amyloid 1-40 and 1-42 peptides underwent the following aggregation conditions before being spotted onto a nitrocellulose membrane and detected using ab201059:
Monomers: 0.3 mg of beta Amyloid peptide was dissolved in 30 µl 100 mM NaOH and incubated at room temperature for 10 minutes. It was then diluted with 970 µl of 1% SDS and boiled for five minutes.
Oligomers: 0.3 mg of beta Amyloid peptide was dissolved in 30 µl 100 mM NaOH and incubated at room temperature for 10 minutes. It was then diluted with 970 µl of 10 mM phosphate buffer pH 7.4 containing 0.02% sodium azide and incubated at room temperature for four days.
Fibrils: 0.3 mg of beta Amyloid peptide was dissolved in 1 ml 50% hexafluoroisopropanol (HFIP) with 0.02% sodium azide. It was then stirred constantly for nine days; the first seven with a cap on and the final two with the cap removed to allow evaporation of the HFIP. Fibrils were then sedimented at 20,000 rpm in a microcentrifuge for 20 minutes and resuspended in 1 ml of PBS + 0.02% sodium azide. -
Immunohistochemistry - Free Floating - Anti-vascular Amyloid 1-42 antibody [mOC31] - Conformation-Specific (ab201059)Image courtesy of Professor Charles Glabe, UC Irvine
Immunohistochemical staining of human brain tissue from a patient with a diagnosis of Alzheimers disease, male, 81 years, 5 hour post mortem index, tangle stage 5, plaque stage B, mini mental status exam score 12. Sections were cut using a vibratome. No antigen retrieval was performed. Free floating sections were stained using using ab201059 at a dilution of 50 ng/mL. The secondary antibody used was a biotinylated goat anti-rabbit at a dilution of 1/225, which was blocked with normal goat serum. The sample was visualized using ABC solution (1 hour incubation) followed by 1-4 minutes of DAB. The sample was mounted and allowed to dry overnight, followed by dehydration in increasingly concentrated ethanol solutions.
-
Negative control (secondary ab only):
Lane 1: beta Amyloid (Aβ) 1-40.
Lane 2: beta Amyloid (Aβ) 1-42.Primary antibody omitted.
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/5000 dilution was used as secondary antibody.
Blocking and diluting buffer: 5% NFDM/TBST.
Exposure time: 30 seconds.
Datasheets and documents
Certificate of Compliance
References (6)
ab201059 has been referenced in 6 publications.
- Paull ML et al. A general approach for predicting protein epitopes targeted by antibody repertoires using whole proteomes. PLoS One 14:e0217668 (2019). PubMed: 31490930
- Liu TC et al. Highly sensitive/selective 3D nanostructured immunoparticle-based interface on a multichannel sensor array for detecting amyloid-beta in Alzheimer's disease. Theranostics 8:4210-4225 (2018). PubMed: 30128048
- Hatami A et al. Familial Alzheimer's Disease Mutations within the Amyloid Precursor Protein Alter the Aggregation and Conformation of the Amyloid-ß Peptide. J Biol Chem 292:3172-3185 (2017). PubMed: 28049728
- Hatami A et al. Monoclonal antibodies against Aß42 fibrils distinguish multiple aggregation state polymorphisms in vitro and in Alzheimer disease brain. J Biol Chem 289:32131-43 (2014). PubMed: 25281743
- McLean D et al. Positron emission tomography imaging of fibrillar parenchymal and vascular amyloid-ß in TgCRND8 mice. ACS Chem Neurosci 4:613-23 (2013). PubMed: 23509918
- Heine M et al. High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes. PLoS One 7:e36258 (2012). PubMed: 22590529